Demonstrating the Potential of Genetic Medicine
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- SonoThera ™, a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines, today announced it will present new data at the 28 th annual American Society of Gene and Cell Therapy (ASGCT) meeting being held May 13-17 th in New Orleans, Louisiana.
This data continues to demonstrate our unique capabilities, including targeted full-length human dystrophin expression in muscle, and delivering oversized genetic payloads in a durable, safe, redosable and noninvasive manner.
Share
An oral presentation will focus on the treatment of Hemophilia A while new data in the poster session targets the treatment of Duchenne Muscular Dystrophy (DMD). Both presentations at ASGCT feature SonoThera's proprietary, nonviral, non-invasive approach using ultrasound-mediated delivery, which enables broad, highly targeted biodistribution of diverse genetic medicine formats without size restrictions, and which enables genetic medicines that can be re-dosed, are safe and well tolerated and are cost-effective.
'We're pleased to be presenting new data at ASGCT highlighting the potential of ultrasound mediated delivery in solving the key challenges in genetic medicine,' said Kenneth Greenberg, PhD, CEO of SonoThera. 'This data continues to demonstrate our unique capabilities, including targeted full-length human dystrophin expression in muscle, and delivering oversized genetic payloads in a durable, safe, redosable and noninvasive manner. We look forward to sharing our latest data at this year's annual meeting.'
Presentation Details:
Oral Presentation: Development of a Novel, Non-Viral Genetic Therapy for Hemophilia A Utilizing Durable, Redosable, and Titratable Approach of Ultrasound-Mediated Delivering of an Oversized Episomal hFVIII DNA Vector.
Session Title: Liver Targeted Genetic Therapies
Presenter: Ivan Krivega, PhD
Session Date/Time: Wednesday, May 14, 2025, 2:30pm – 2:45pm CT.
Room: 288-290
Poster Presentation: Non-Viral Genetic Medicine for Targeted Delivery of Full-Length Dystrophin to Skeletal, Cardiac, and Diaphragm Muscles in DMD Mouse Models and Non-Human Primates.
Session: Disease Models and Clinical Applications: B8 - Musculo-skeletal Diseases
Presenter: Ivan Krivega, PhD
Session Date/Time: Thursday, May 15, 2025, 5:30pm – 7:00pm CT
Location: Poster Hall, Hall I2
About SonoThera™
SonoThera is a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines. Our nonviral technology is designed to overcome all prevailing limitations of genetic medicine, enabling a pipeline of products which leverages our novel capabilities. Using ultrasound-mediated delivery (UMD), we are developing a proprietary, non-invasive approach which enables broad, highly targeted biodistribution, delivery of diverse genetic payloads without size restriction, in a redosable manner designed to be safe, well-tolerated and cost-effective.
Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera is headquartered in South San Francisco.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,' stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. SYMPOSIA AND POSTERS COMPANY SPONSORED SYMPOSIUM (June 13, 13:30–14:30 – Room: Meeting Academy M1) "Breath of change: redefining respiratory allergy care with remission in sight" Chair: Prof. Adnan Custovic, United Kingdom - 'Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift' Speaker: Prof. Guillaume Lezmi, France - 'From symptom control to disease remission: a new vision for allergic asthma' Speaker: Prof. Oliver Pfaar, Germany - 'Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis' Speaker: Prof. Randolph Brehler, Germany COMPANY SPONSORED SYMPOSIUM (June 14, 14:30–15:00 – Room: Boisdale) ' Myth busting in peanut allergy: separating fact from fiction ' Speakers: Dr Aikaterini Anagnostou, United States of America, and Dr Pablo Rodríguez del Río, Spain POSTERS Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. ABOUT THE EAACI CONGRESS The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit
Business Wire
42 minutes ago
- Business Wire
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks Share EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively 2. The study assessed the long-term safety of EPYSQLI in PNH patients by evaluating the consistency of safety outcomes, particularly serious adverse events (SAEs) between the initial 52-week Phase 3 study period and the extended treatment (ET) period, spanning from 52 weeks to up to 158 weeks. The same maintenance dose of 900 mg EPYSQLI was administered every 2 weeks. A total of 46 patients from the Phase 3 study received ET. During ET, seven patients (15.2%) experienced a total of 14 SAEs with no occurrence of fatal cases, and all patients fully recovered without permanently discontinuing the treatment. The exposure-adjusted event rate (EAER) was comparable between initial 52-week period and ET period (EAER were 0.13 and 0.17, respectively), and there was no statistically difference between initial 52-week and ET period in EAER (p-value = 0.76). The study is consistent with the findings of the Phase 3 study with no newly identified safety signals and no fatal cases occurred throughout the entire treatment period with all SAEs resolving completely. Details of the abstract are as follows 3: Abstract title: Long-Term Safety of SB12 in Paroxysmal Nocturnal Hemoglobinuria: Up to 2-year Extension Treatment Safety Data Abstract number: PB2811 Type: Publication Only Session title: Bone marrow failure syndromes incl. PNH – Clinical Author(s): Jun Ho Jang, Siook Baek, Yumin Baek, Jinah Jung, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Soo Min Lim Besides approval by the EC, EPYSQLI is also approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) as a biosimilar to Soliris. In countries where EPYSQLI is approved and available, EPYSQLI may not be prescribed and/or dispensed for its unapproved other indications for which Soliris is approved. About EPYSQLI (Eculizumab Biosimilar) in the European Union (EU) EPYSQLI is indicated in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). EPYSQLI is not approved for and should not be used for the treatment of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). EPYSQLI must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological disorders or renal disorders. EPYSQLI EU Important Safety Information The EU Summary of Product Characteristics for EPYSQLI includes the following Special warning and Precautions: Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 are recommended in preventing the commonly pathogenic meningococcal serogroups. Vaccine against serogroup B where available is also recommended. Patients must receive vaccination according to current national vaccination guidelines for vaccination use. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Other Systemic Infections Patients may have increased susceptibility to other type of serious infections, especially with Neisseria and encapsulated bacteria. Infusion Reactions Administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered. Anticoagulant therapy Treatment with eculizumab should not alter anticoagulant management. PNH Laboratory Monitoring PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). aHUS Laboratory Monitoring aHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). Treatment Discontinuation for PNH If patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Treatment Discontinuation for aHUS If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. The most common adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was found to be meningococcal infection. Refer to the Summary of Product Characteristics for EPYSQLI's full safety information.
Business Wire
2 hours ago
- Business Wire
Dassault Systèmes' 3D UNIV+RSES at the 2025 Paris Air Show: Transforming Aerospace and Defense with AI-Powered Generative Experiences
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, today announced it will showcase how its 3D UNIV+RSES are transforming design, production and operations to shape the future of the aerospace and defense industry, at the Paris Air Show June 16-22, 2025. As challenges in complexity, safety, sovereignty, skills, sustainability and speed to market require industry to adopt new working methods across the value chain, 3D UNIV+RSES enable industry to imagine and develop new products and services with experience at the core. Their unique combination of modeling, simulation, data science and AI-generated content blend virtual and real worlds in a secured environment for experimenting, collaborating, learning and inventing while protecting intellectual property. At chalet B159, Dassault Systèmes will feature the transformative power of virtual twins and AI-enabled generative experiences integrated across the aircraft lifecycle, accelerating design through to operations. Demonstrations will tackle the different challenges the industry faces today, including workforce training and capturing and preserving the expertise that will empower a new generation. Highlights and demonstrations include: 3DEXPERIENCE platform capabilities for building an aircraft with AI-powered generative experiences, automating production, testing and optimizing an airframe for certification, ensuring quality, reducing maintenance costs, and more Panels on how the virtual world is driving a paradigm shift across defense, the supply chain, production, advanced air mobility, and education with participants from Airbus Defense and Space, the French Procurement agency (DGA), NIAR, Aciturri, SABCA, TAAC Aerospace Technologies, UUDS Group, Beyond Aero, UrbanV, Vertical Aerospace, Group ISAE and more A contest inviting attendees to try to win prizes by using a mobile web application to scan QR codes to collect iconic virtual twins of innovations by Dassault Systèmes customers 'The future of aerospace and defense requires new ways to bring machines, drones, satellites, equipment and intelligent systems to life, and to redefine how the world can benefit from them. Our 3D UNIV+RSES propel this disruption forward with generative AI, knowledge and know-how, catalyzing a new era of industrial transformation that delivers performance, resilience and sovereignty,' said David Ziegler, Vice President, Aerospace and Defense Industry, Dassault Systèmes. Since 1981, Dassault Systèmes has been the partner of choice to the aerospace and defense industry, enabling transformative business processes across all disciplines and the value chain that have changed how they work and innovate. With science-based solutions for the commercial aviation, space, defense, aerospace propulsion, supplier, airport and airline sectors, the company's technology is deployed across the industry worldwide, bringing the virtual world to nearly every program today. Dassault Systèmes in the aerospace and defense industry: ABOUT DASSAULT SYSTÈMES
